Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CN5Q | ISIN: US91864C1071 | Ticker-Symbol: 2AB
Stuttgart
06.06.25 | 10:50
0,840 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BARINTHUS BIOTHERAPEUTICS PLC ADR Chart 1 Jahr
5-Tage-Chart
BARINTHUS BIOTHERAPEUTICS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,8600,90506.06.

Aktuelle News zur BARINTHUS BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.05.Barinthus Biotherapeutics plc. - 10-Q, Quarterly Report4
07.05.Barinthus Biotherapeutics plc. - 8-K, Current Report1
20.03.Barinthus Biotherapeutics plc. - S-8, Securities to be offered to employees in employee benefit plans2
20.03.Barinthus Biotherapeutics plc. - 10-K, Annual Report2
20.03.Barinthus Biotherapeutics Plc Full Year Loss Narrows-
BARINTHUS BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
20.03.Barinthus Biotherapeutics plc. - 8-K, Current Report2
20.03.Barinthus Biotherapeutics: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments834Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000)...
► Artikel lesen
06.03.Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11241NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.About...
► Artikel lesen
10.01.Barinthus Bio's UK COO, CFO To Leave, Plans To Cut 65% Headcount To Expand Cash Runway-
10.01.Barinthus Bio shifts focus, cuts workforce to extend cash runway1
10.01.Barinthus Biotherapeutics: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update402Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identifiedExtending...
► Artikel lesen
10.01.Barinthus Biotherapeutics plc. - 8-K, Current Report-
15.11.24Arbutus Biopharma Corporation: Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B389Significantly greater mean declines in HBsAg levels (p 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom...
► Artikel lesen
15.11.24Barinthus Biotherapeutics: Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion182Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. OXFORD, United...
► Artikel lesen
06.11.24Barinthus Biotherapeutics: Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results157OXFORD, United Kingdom, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that...
► Artikel lesen
01.10.24Barinthus Biotherapeutics: Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer122Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.Interim data update for HBV003 anticipated in Q4 2024.Data update...
► Artikel lesen
24.09.24Barinthus Biotherapeutics: Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease337Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people globally suffer from celiac disease, for which...
► Artikel lesen
21.06.24Pre-market Movers: Sarepta Therapeutics, Kaival Brands, Barinthus Biotherapeutics, Solid Biosciences, Molecular Partners691FOSTER CITY (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.05 A.M. ET).In the Green Sarepta Therapeutics, Inc. (SRPT) is up over 40%...
► Artikel lesen
12.06.24Barinthus Biotherapeutics: Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections168The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized.The pipeline prioritization is expected to result in a reduction in workforce of approximately...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1